AI personal finance tools offer personalized advice, address financial embarrassment, and make complex money concepts accessible by 2026.
·
·
4 min read
Pelacarsen cut Lp(a) by 80%, but lacked MACE proof. This shifts drug trials to direct clinical benefits, not just biomarkers, for heart disease. What's next
·
·
8 min read
Lp(a) drug development faces hurdles. See why new therapies like ASOs are changing cardiovascular care and what to watch for by 2026.
·
·
9 min read
New therapies are targeting Lp(a), a genetic heart risk. Learn about 80% reductions in trials, ESC guidelines, and what's next for patients.
·
·
7 min read
OEM deception in military AI creates critical cybersecurity risks. Learn why third-party AI modules threaten national security by 2026.
·
·
7 min read
Why do Ebola responses fail in 2026? Learn how to fix global health's broken rapid response, deploying teams within hours, not days.
·
·
6 min read
Employee disengagement costs businesses profit. Learn how to mitigate this workplace risk, reduce turnover by 15%, and boost profitability.
·
·
7 min read
Can AI ease money stress? 40% avoid financial planning due to anxiety. See how AI offers judgment-free guidance, helping more people by 2026.
·
·
8 min read
New to AI finance? Learn how AI apps and robo-advisors manage money, spot fraud, and what to watch for in 2026. Improve your financial health.
·
·
7 min read
Novartis's Pelacarsen drug failed Phase 3 trials. We explain why it matters for future heart disease treatments and what's next for clinical trials.
·
·
7 min read